Nanobiotix announces encouraging results for its lead product NBTXR3

It was at the 2022 edition of the American Society for Clinical Oncology (ASCO) that Nanobiotix presented new clinical data on its flagship product NBTXR3. The biotechnology company, specializing in nanomedicine, took advantage of this annual medical congress to highlight its radio enhancerto be included in the treatment of all solid tumours: administered by intratumour injection, the product is activated through radiotherapy.

Encouraging data

The results, which relate to two phase 1b/2 trials (intermediate stage of clinical trials) and are led by the company’s former partner PharmaEngine in Asia, reveal encouraging data for the combined use of NBTXR3 and chemotherapy .

Thus, in 12 patients with advanced stage 4 head and neck cancer, the combination of NBTXR3 with chemotherapy was feasible and showed a response rate – the percentage of patients whose tumor shrank in defined proportions – 58.3%. The disease control rate, ie the rate of patients who saw the extent of the tumors stabilize, came out at 100%.

The second trial this time involved patients with rectal cancer, the second leading cause of cancer-related death in the United States. In a sample of 34 people, the disease control and response rates were 100% and 35.5% respectively. The combination of NBTXR3 and preoperative chemotherapy enabled 96% of patients to have complete surgical excision.

Comprehensive treatment approach

Nanobiotix also presented a poster at ASCO, describing the plan for the ongoing pivotal phase III study NANORAY-312. He is evaluating NBTXR3 in the treatment of elderly and frail patients, not eligible for platinum-based chemotherapy and suffering from head or neck cancer. By prioritizing this ongoing study, Nanobiotix intends, according to its founder and leader Dr. Laurent Levy, “to build a comprehensive approach to the treatment of this cancer”.